Non-alcoholic fatty liver disease can promote development of coronary artery calcification

NewsGuard 100/100 Score

Data revealed today at The International Liver CongressTM 2015 show that non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

Findings showed that the impact of NAFLD varies significantly depending on the severity of CAC at baseline. In those without CAC, NAFLD significantly affected the development of atherosclerosis; however, in patients with existing CAC at baseline NAFLD did not affect progression of the disease.

A total of 1,732 patients were included in the study:

  • Out of 1,732 patients who underwent serial CAC score evaluation, 847 patients had NAFLD and 885 patients did not have NAFLD.
  • The baseline CAC score was higher in those with NAFLD and a greater number of these patients displayed progression (48.8% vs. 38.4%, p<0.001 in subjects with vs. without NAFLD)

  • NAFLD was prospectively associated with progression of CAC score (OR 1.53, 95% CI: 1.26-1.85, p<0.001)

  • Analysis according to the severity of NAFLD showed that NAFLD in its more severe form promotes progression of CAC (adjusted OR 1.77, 95% CI: 1.08-2.88, p=0.022)

Source: European Association for the Study of the Liver

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
RNA Therapies in Liver Disease: Insights from Ochre Bio's CEO